Page 108 - 2021_06-Haematologica-web

N.A. Heerema et al.
defined as ≥3 aberrations, and the presence of a translo- cation are shown in Table 2. Of the 85 cases with a translocation, 46 also had a complex karyotype and 39 did not. Unbalanced translocations were more frequent in cases with a complex karyotype (41/46), while bal- anced translocations were more frequent in non-complex cases (24/39). No translocation was identified in 244 cases; 237 of these had non-complex karyotypes.
Translocations and complex karyotypes occur more frequently in unmutated IGVH chronic lymphocytic leukemia
IGHV data were available for 292 patients; data were not available for 37 patients (Table 3). Unmutated IGHV was found in 148 patients; 51 (34.5%) had a transloca- tion, and 97 (65.5%) did not have a translocation; 31 (20.9%) had complex karyotypes (≥3 aberrations), while
Table 1. The patients’ baseline characteristics and associations with time to first treatment.
Patients’ characteristics (n=329) N.
Age at diagnosis, years
Mean (SD) Median (range)
Sex
Male 208
Female 121
Complexity
Median (range)
< 3 Abnormalities 276 ≥3 Abnormalities 53
Translocation
Neither 244 Balanced 29 Unbalanced 56
Rai stage at diagnosis
0-2 296 3-4 32
IGHV unmutated
No 144
Yes 148
Trisomy 3
No 312 Yes 17
Trisomy 8
No 314
Yes 15
Trisomy 12
No 251 Yes 78
Del(13q)
No 155
Yes 174
Del(17p)
No 298 Yes 31
Del(6q)
No 315
Yes 14
Del(11q)
No 285 b Yes 44
-microglobulin >3.5 mg/L 2
No 165
Yes 18
WBC, x109/L
Median (range)
60 (11) 60 (34-88)
%
63.2
36.8
HR 95% CI
1.00 0.99-1.02
0.90 0.64-1.27
P-value
0.64
0.55
<0.001 <0.001
<0.001
<0.001
<0.001
0.88
0.003
0.29
0.15
0.002
0.13
<0.001
0.025
<0.001
1 (0-17) 1.16 83.9
16.1 2.92
74.2
9.1 2.64*
16.7
90.2
9.8 3.73
49.3
50.7 3.48
94.8
5.2 1.06
95.4
4.6 2.53
76.3
23.7 1.23
47.1
52.9 0.78
90.6
9.4 2.10
95.7
4.3 1.73
86.6
13.4 2.92
90.2
9.8 2.33
1.11 -1.22 1.98-4.31
1.87-3.71
2.32-5.99
2.38-5.08
0.49-2.27
1.36-4.71
0.84-1.81
0.56-1.09
1.31-3.37
0.85-3.55
1.98-4.31
1.11-4.88
17.5 (2.9-392.6)
1.72** 1.35- 2.20
HR:hazard ratio;95% CI:95% confidence interval;SD:standard deviation;WBC:white blood cell count.The results for trisomy 3,trisomy 8,trisomy 12,del(13q) del(17p,del(6q) and del(11q) were determined from fluorescence in situ hybridization data.Trisomy 3 was determined using the BCL6 probe,trisomy 8 using the MYC probe,trisomy 12 using the D12Z3 (centromere 12) probe, del(13q) using the D13S319 probe, del(17p) using the TP53 probe, del(6q) using the MYB and/or SEC63 probes and del(11q) using the ATM probe.*HR for balanced and unbalanced translocations combined compared to no translocations, **HR for log-transformed WBC.
1610
haematologica | 2021; 106(6)